RSV IMMUNISATION FOR INFANTS IN EUROPE: ARE OUR HEALTH SYSTEMS READY?
EHMA publishes a paper based on expert insight from across Europe, exploring the challenges and opportunities of implementing RSV immunisation programmes in different country contexts.
Why Vaccinate Healthy 2- to 17-Year-Olds Against Influenza?
On February 2023, the French National Authority for Health (HAS) recommended extending flu shots to children aged 2-17 years without comorbidities.
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear.
International Pediatric COVID-19 Severity Over the Course of the Pandemic
This cohort study suggested that while intensive care unit admission decreased over the course of the pandemic in all age groups, ventilatory and oxygen support did not decrease over time in children aged younger than 5 years.
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nirsevimab is a monoclonal antibody that binds to the RSV fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season.
The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.
Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study
Data on the protection conferred by COVID-19 vaccination and previous SARS-CoV-2 infection against omicron (B.1.1.529) infection in young children are scarce.
|
ESWI Airborne: Burden of Disease
Burden of disease - The economic and societal impact of acute respiratory viruses
The shocking numbers of babies and children who die, or who are in need of care, coupled with the rising number of undiagnosed older adults puts a significant burden from RSV on health systems.
Diagnosis of type 1 diabetes after SARS-CoV-2 infection: Researchers find possible correlation
Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern, have now investigated whether there is a temporal association between infection with the SARS-CoV-2 virus and the development of type 1 diabetes.
Reaching for New Heights: Breaking Down Influenza Trends and Prevention Efforts
Did you know that in female children, influenza pneumonia is the second most common cause of death?
Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
Early-life severe RSV infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear.
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study
Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available.
